• English
  • Korean
  • Chinese
市場調査レポート - 234123


Bydureon FDA Approval: Physician Opinion

発行 Datamonitor
出版日 ページ情報 英文
FDAによるBydureonの承認:医師の見解 Bydureon FDA Approval: Physician Opinion
出版日: 2012年02月24日 ページ情報: 英文

当レポートでは、84名の内分泌科医およびPCP(Primary Care Physician)を対象に、先頃FDAに承認された糖尿病治療のための週1回投与型エキセナチド「Bydureon」(Amylin社・Alkermes社)に対する各種見解を調査し、その結果を概略下記の構成でお届けいたします。


  • 1ヶ月あたりに診療する2型糖尿病患者数
  • 週1回投与型エキセナチド「Bydureon」への認識レベル
  • 好んで処方する薬剤
  • 「Bydureon」の安全性(および忍容性)に関する潜在的懸念
  • 「Bydureon」を処方する治療アルゴリズムの段階
  • 発売1年後に「Bydureon」による治療を行う患者人口の予測
  • 「Bydureon」と併用できる可能性のある薬剤クラス(3種)
  • 医師の見解:「Bydureon」の発売とその他の市場動向による米国のGLP-1アゴニストの投薬を受ける患者数への影響


  • 人口動態
  • PCPの間では認知度が低い:マーケティング上の課題となる可能性
  • Bydureonの有効性に関する印象:認知度によって異なる
  • Bydureonを良く知る医師の間では、忍容性の課題が安全性への懸念を上回る
  • Bydureonの利用への高い期待は、経験値があがるにつれ落ち着く見通し
  • 内分泌科医はPCPに比べ早い治療段階でBydureonを使用する傾向
  • 経口抗糖尿病薬と併用される可能性が高い
  • BydureonによってGLP-1アゴニスト市場の拡大を期待する医師
  • 総論


Physician survey of 84 endocrinologists and primary care physicians on their impressions and expected use of Amylin's and Alkermes's Bydureon (once-weekly exenatide)



On January 27, 2012, the FDA approved Amylin's and Alkermes's Bydureon (once-weekly exenatide) for adults with type 2 diabetes. This survey shows broad enthusiasm for the drug among endocrinologists and PCPs, but initial excitement may wane as physicians fully weigh such factors as comparative efficacy with Novo Nordisk's Victoza (liraglutide), injection device size and convenience, and cost.


  • Physicians were asked to assess their impressions of Bydureon in terms of efficacy, safety, tolerability, expected use, and other important factors
  • Key questions are broken down by specialty or familiarity to highlight difference in physician perceptions


  • Datamonitor anticipates that the initial enthusiasm will ultimately be muted once physicians gain experience with the drug. Nevertheless, a once-weekly antidiabetic agent clearly represents an attractive option for type 2 diabetes patients, and physicians expect the drug to be a welcome addition to their armamentarium.


  • Assess physicians' opinions of Bydureon as compared with Amylin's twice-daily Byetta (exenatide) and Novo Nordisk's once-daily Victoza (liraglutide)
  • Determine physicians' expectations for Bydureon's uptake, line of therapy, and use in combination with other antidiabetics
  • Evaluate how Bydureon may expand the overall market for GLP-1 agonists





  • Demographics
  • Limited familiarity with PCPs could present a marketing challenge
  • Impressions of Bydureon's efficacy differ based on familiarity
  • Tolerability issues trump safety concerns among physicians familiar with Bydureon
  • High expectations for Bydureon use will likely come down with increased experience
  • Endocrinologists expect to use Bydureon in earlier line of therapy compared to PCPs
  • Combination use with oral antidiabetics is likely
  • Physicians expect Bydureon to expand the GLP-1 agonist market
  • Conclusion


  • Report methodology
  • Datamonitor consulting
  • Disclaimer


  • Figure: On average, how many patients with type 2 diabetes do you treat per month?
  • Figure: How familiar are you with Bydureon (once-weekly exenatide)?
  • Figure: For each attribute below, please select the one drug that you would prefer to prescribe, based on performance (or predicted performance) on that attribute
  • Figure: Please select the one drug that you would prefer to prescribe, based on efficacy (HbA1c lowering ability)
  • Figure: Please rank the following potential safety (and tolerability) issues you are most concerned about with Bydureon on a scale of 1 to 7, where 1 is the issue of greatest concern and 7 is the issue of least concern
  • Figure: Please select the one drug that you would prefer to prescribe, based on injection device
  • Figure: Where in the treatment algorithm do you think you will most commonly prescribe Bydureon?
  • Figure: Please consider your hypothetical Bydureon-treated patient population a year post-launch. What percentage of the Bydureon-treated patient population do you expect to have previously been treated with each of the following options?
  • Figure: Please choose up to three drug classes with which Bydureon could be used in combination. If there are more than three classes, please select the three most likely
  • Figure: Please give your opinion on how the introduction of Bydureon, and any other market trends, will impact on the number of patients on GLP-1 agonists in the US
Back to Top